CRP for the Clinician

Size: px
Start display at page:

Download "CRP for the Clinician"

Transcription

1 CRP for the Clinician J. C. Kaski, D.Sc., M.D., D.M (Hons), F.E.S.C., F.R.C.P., F.A.C.C. F.A.H.A Professor of Cardiovascular Science Head, Cardiovascular Sciences Research Centre St George s, University of London, London, UK Conflict of Interest: None

2 Inflammation and Atherosclerosis Image courtesy of Roche Inflammation plays a central role in all phases of atherosclerosis CRP is a good marker of inflammation and an excellent research tool

3 Stratification of Cardiovascular Risk Current Challenges Traditional risk factors have been shown to predict coronary heart disease and cardiovascular disease (CVD) in a large number of prospective observational studies (Wilson PW et al. Circulation. 1998;97: ) High v. Low risk issues There is interest in developing more effective strategies to identify the true risk of persons considered to be at an intermediate level of risk for CHD based on conventional assessment. Intermediate risk is an arbitrary/dynamic category that is likely to change as risk assessment becomes more efficient CRP may be used to refine estimates of cardiovascular risk stratification (Ridker PM et al. NEJM 1987; 336: ; Ridker PM et al. N Engl J Med. 2000;342: )

4 Characteristics of Clinically Useful Markers of Cardiovascular Risk Relate to pathogenesis of CV disease Provide independent information over and above that afforded by conventional markers of risk Cost-effective, practical and reproducible Validated in real life settings, with a large area under ROC curve Useful for patient risk reclassification

5 What Clinicians Want to Know Before Using a New Biomarker of Cardiovascular Risk Useful for patient management? Helps with therapeutic decisions/primary prevention? Changes clinical practice as a result of its use for screening, diagnosis, prognosis, or treatment

6 CRP and Cardiovascular Risk Marker of Risk Associated with the disease but need not be causally linked; it may be a measure of the disease process itself Risk Factor Associated with a disease because it is in the causal pathway leading to the disease Pathogenic Factor A cause of the disease

7 C-Reactive Protein is a Marker of Cardiovascular Risk In apparently healthy subjects, individuals with conventional risk factors for CAD and in patients with established cardiovascular disease (i.e. stable and unstable CAD), increased hs-crp levels have been shown to be an independent marker of risk No controversial issues here!

8 EVIDENCE AGAINST A PATHOGENIC ROLE FOR CIRCULATING CRP IN ATHEROSCLEROSIS Animal and in vitro studies Human genetic studies Hirschfield GM et al. Transgenic human C-reactive protein is not proatherogenic in apolipoprotein E-deficient mice. Proc Natl Acad Sci 2005 Koike T et al. Human CRP does not promote atherosclerosis in transgenic rabbits. Circulation 2009; 120: Taylor KE et al. C-reactive proteininduced in vitro endothelial cell activation is an artefact caused by azide and lipopolysaccharide. Arterioscler Thromb Vasc Biol 2005;25:

9 MENDELIAN RANDOMISATION STUDIES The CRP /CHD Genetics Collaboration (BMJ 2011; 342:d548) confirmed in > CAD patients and > controls that: 1.Genetically raised concentrations of CRP are unrelated to conventional risk factors and risk of CAD 2.CRP concentration itself is unlikely to be even a modest causal factor in CAD Associations between CRP and CAD reported in prospective studies are likely to arise from reverse causality or residual confounding

10 Predictive Role of CRP in ACS CRP predicts inhospital patient outcome (n=34) Liuzzo. NEJM 1994, death at 15 d - Morrow [TIMI 11 A; n= 437] JACC 1998 and Montalescot [ESSENCE (n=68) ] (1999) death+mi+ua (n=105,15 mg/l) Ferreiros Circulation 1999 and 30-day mortality GUSTO-IV ACS Study (>7000 pts) James et al. JACC 2003 hs-crp level assessed at hospital admission in 1128 ACS patients was a modest predictor for 30-day mortality Combined with the GRACE risk score, CRP (cut off 22 mg/l) improved risk classification Schiele F et al. Eur Heart J 2010;31:

11 Clinical Usefulness of hs-crp for Risk Prediction in Patients with ACS Nested case-cohort study within OPUS-TIMI 16 to evaluate hscrp in ACS. hscrp measured in 3225 ACS patients and compared in patients who suffered an adverse cardiac outcome within 10 months of study entry and those who did not. Increased baseline concentrations of hscrp were strongly associated with mortality and heart failure across the ACS spectrum. Index diagnosis-specific CRP cut-points were identified and predictive value of the marker differed according to timing of CRP measurement BM Scirica et al. Clinical Application of C-Reactive Protein Across the Spectrum of Acute Coronary Syndromes Clin Chem. 2007;53:

12 A Comparative Study Of Multiple Inflammatory Markers For Risk Prediction In Acute Coronary Syndrome SIESTA Study J.C. Kaski et al. Atherosclerosis 2010 Prospective cohort study of NSTE-ACS patients admitted to 25 hospitals in Spain 610 patients (73% men) 36% unstable angina and 64% NSTEMI 360-day follow-up AIMS To compare the relative prognostic ability of different inflammatory biomarkers To assess whether inflammatory biomarkers contribute additional independent information to that of clinical risk scores

13 CRP DOES NOT IMPROVE TIMI RISK SCORE S C-STATISTIC In the SIESTA study, the area under the ROC curve for TIMI risk score was 0.58, and was not improved by the addition of CRP as a new variable (p= 0.92) JC Kaski et al. Atherosclerosis 2008 Eggers KM et al Am Heart J An increase of the C-statistic was achieved only after the addition of GDF-15 (0.81, P =.003) and cystatin C (0.81, P =.035) CRP did not improve prognostic discrimination in ACS patients- CRP modified TIMI risk score TIMI risk score Reference curve

14 Normal hs-crp levels at the onset of first STEMI in 41% of cases (a multiethnic case-control study) In over 40% of 887 STEMI patients admitted within 6 h from symptoms onset, hscrp serum levels were <2 mg/l. The number of patients with low CRP prior to the AMI could be even larger considering that hscrp is likely to have increased before sampling as a result of the acute process in at least some patients Using a 2 mg/l cut point, the measurement of hscrp prior to the event would not have predicted 41% of MIs in these patients without evidence of previous CAD Cristell N et al. JACC 2011.

15 Use of CRP in the setting of ACS - ESC Guidelines for the Management of NSTE-ACS Eur Heart J 2011 The committee acknowledges the predictive role of CRP in ACS, as suggested in numerous clinical studies No recommendation is made regarding the use of CRP for diagnosis of ACS or patient risk stratification in this setting

16 CRP Levels and Clinical Outcome in Stable Angina PEACE (Prevention of Events with Angiotensin Converting Enzyme inhibition) Trial 3771 stable CAD patients Trandolapril vs placebo Elevated hs-crp >1 mg/l is a predictor of CV events (death, AMI and stroke) High CRP predicts new onset heart failure High CRP patients did not benefit from ACEI CUMULATIVE INCIDENCE OF DEATH, AMI OR STROKE (%) P<0.001 CRP >3 mg/l CRP 1-3 mg/l CRP <1 mg/l MONTHS Sabatine MS et al. Circulation 2007; 115:

17 Evaluating the Quality of Research into a Single Prognostic Biomarker: A Systematic Review and Meta-analysis of CRP in Stable CAD Hemingway H et al. PLoS Med 2010; 7(6): e doi: studies, 61,684 patients and 6,485 outcome events. Pooled relative risk (RR) for the top versus bottom third of CRP distribution: 1.97 (95% CI ) (heterogeneity +) Only 13 studies adjusted for conventional risk factors and these showed a RR of 1.65 (95% CI ). Adjusting for publication bias (for which there was strong evidence; p =0.001) reduced the RR to 1.19 (95% CI ). Conclusion: Reporting and publication bias make any independent association between CRP and prognosis among patients with stable CAD sufficiently uncertain that no clinical practice recommendations can be made

18 CRP and CV Risk in Population Studies The Emerging Risk Factors Collaboration Study RR CAD 1.63 ( ) 1.37 ( ) 1.23 ( ) RR Stroke 1.44 ( ) 1.27 ( ) 1.32 ( ) RR Vascular mortality Lancet 2010; 375: An Individual Participant Meta-Analysis Individual records of 160,309 Adjustment people without Age a history & sex of Risk CVD (27,769 factors fatal Fibrinogen or non-fatal outcomes) from 54 prospective studies. Within-study regression analyses adjusted for within-person variation in risk factor (RF) levels Results CRP concentration was linearly associated with conventional RFs and other inflammatory markers and nearly log-linearly with the risk of ischaemic vascular disease and non-vascular mortality (i.e. cancer, trauma and respiratory) NON-SPECIFIC RISK MARKER 1.71 ( ) 1.55 ( ) 1.34 ( ) Adjustment for conventional RFs and plasma fibrinogen considerably weakened the associations RR Non-vascular 1.55 ( ) 1.54 ( ) 1.34 ( ) of CRP mortality with risk of CAD, ischaemic stroke and non-vascular death

19 No Incremental Coronary Risk Prediction Using CRP and Other Novel Markers ARIC (AR Folsom et al. Arch Intern Med 2006) Case-cohort study, n= (45-74 yrs) Events: Death, AMI, DEATH 5 yr f-up Conventional RFs vs 19 novel biomarkers (including CRP) - AUC (ROC) to assess additional contribution beyond RFs for CAD (AUC 0.8) CRP did not add significantly to the AUC, and neither did most other novel risk factors MAJOR CV EVENTS Routine measurement of novel biomarkers is not warranted for risk assessment Conventional RFs 10 biomarkers measured in RFs + Log CRP Probability of Event Probability of Event Men TJ Wang et al. NEJM subjects (general unselected population) attending a routine examination cycle of the Framingham Heart Study. CRP, BNP, NT pro ANP, Women renin, aldosterone, fibrinogen, PAI-1, D- dimer, homocysteine, etc. Multiple biomarkers DO NOT contribute substantial additional information for the prediction of Risk Decile major CV events and death

20 Better Methodologies Required for Assessment? Descriptive statistics such as the relative risk of a new factor that is added to a multivariable prediction and the c statistic can be inadequate to show how such new factors may mediate risk in a population setting. New methods may help to better to quantify such risk Improved patient risk reclassification using the Reynolds Risk Score (CRP and Parental history)- PM Ridker et al. JAMA. 2007;297: C-Reactive Protein resulted in moderate improvement in reclassification of risk Cardiovascular Risk in the Framingham Heart Study Wilson PW et al. Circ Cardiovasc Qual Outcomes. 2008;1:92-97

21 Novel and Conventional Biomarkers for Prediction of Incident Cardiovascular Events in the Community Melander O et al. JAMA. 2009;302(1): participants (age of 58) from the population-based, prospective epidemiologic Malmo Diet and Cancer study, without CVD at baseline ( ). Contemporary set of biomarkers, 12.8 yrs f-up, and stateof-the-art statistical approach For cardiovascular event prediction, CRP and N-BNP together improved the conventional risk factor C statistic of by only (P=0.04). The whole set of significant biomarkers together increased the C statistics by ~0.01 RECLASSIFICATION The biomarkers changed the risk classification, based on conventional factors, for only 8% of patients for CV risk and 5% for coronary risk. Net improvement in reclassification was not significant for CV events Correct reclassification was confined to down-classification of individuals without events rather than up-classification of those with events.

22 JUPITER Study Ridker et al. NEJM 2008 (Justification for the Use of statins in Primary prevention: an International Trial Evaluating Rosuvastatin) A randomized, double-blind, placebo controlled, multicenter trial conducted at 1315 sites in 26 countries 17,802 apparently healthy men and women with LDLcholesterol levels <130 mg per deciliter (3.4 mmol/l) and hs- CRP levels 2.0 mg per liter Patients were randomized to rosuvastatin, 20 mg daily, or placebo An event-driven trial designed to continue until 520 confirmed primary end points had been documented. The trial was stopped after a median follow-up of 1.9 years

23 CAN CRP GUIDE THERAPY? - JUPITER Study Statin therapy prevented first-ever events in apparently healthy subjects with LDL-C <130 mg/dl but elevated hscrp (2mg/L) NNT to prevent 1 end-point= 25 Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult 2009 recommendations J Genest et al. Can J Cardiol 2009;25: Ridker PM et al. N Engl J Med 2008;359: Relative hazard reductions in the rosuvastatin group were similar for women (46%) and men (42%) and were observed in every subgroup evaluated (age, ethnic group, traditional risk factors, and Framingham risk score)

24 Problems with JUPITER METHODOLOGICAL Lack of a low-crp arm Rosuvastatin lowers both LDL-C and hs-crp ~40% of subjects had metabolic syndrome Early termination why? 240 serious events (truncated trials overestimate effects) Questionable interpretation of mortality data. Curves converging at end of trial CLINICAL AND EPIDEMIOLOGICAL ISSUES Lack of detailed CV mortality data - No SCD reported- and identical CV mortality in placebo and rosuvastatin groups Low fatal to non-fatal MI ratio and very low case fatality rate (<9%) mainly in the placebo group (rosuvastatin 29%)

25 JUPITER Study Findings not Endorsed by Results of the Heart Protection Study In 69 UK hospitals, men and women yrs at high risk of CV events were randomised to simvastatin 40 mg/d or placebo for 5 yrs. Patients were categorised into six baseline CRP groups. Primary endpoint for subgroup analyses: major vascular events, i.e. coronary death, MI, stroke,pci/cabg Effect of simvastatin allocation on vascular events by baseline concentration of CRP Simvastatin treatment significantly reduced the incidence of first major vascular events, 24% (95% CI 19 28) There were significant risk reductions in each of the baseline CRP groups, including participants with CRP <1.25 mg/l (29% risk reduction, 99% CI 12 43; p<0.0001). Participants with high baseline CRP had higher mean BMI, LDL cholesterol, and TG concentration, and lower mean HDL-cholesterol concentration Lancet 2011; 377:

26 Peter S. Sever*, Neil R Poulter, Choon L Chang, Aroon Hingorani, Simon McG Thom, Alun D Hughes, Paul Welsh, Naveed Sattar, on behalf of the ASCOT Investigators *Imperial College London Evaluation of CRP, prior to and on-treatment, as a predictor of benefit from atorvastatin: Nested case control study from ASCOT 485 cases (355 CHD & 130 stroke) matched with 1,367 controls - CRPmeasured at baseline and 6 months Investigator-led, multinational randomised controlled trial conducted in hypertensive patients, yrs, with no prior history of CHD, but with 3 additional cardiovascular risk factors Summary - Inclusion of CRP into a modified Framingham risk model in the whole cohort very modestly improved risk prediction Baseline CRP was not an indicator of the effect of atorvastatin on CV outcome Lowering LDL-C at 6 months but not CRP- correlated with a reduction in CV events CONCLUSION -The results do not support current proposals to measure CRP in the clinical setting to assign statins to individuals on the basis of an elevated CRP alone, or to monitor CRP levels as an indicator of the efficacy of statin treatment

27 USA Guidelines for hscrp testing SHAPE (Society for Heart Attack Prevention and Eradication) The new guidelines recommend CRP testing for all intermediate- and high-risk individuals and elevate the patient's risk category if CRP >3 mg/l. The ACCF/AHA writing committee finds that CRP generally adds little prognostic information to traditional risk factors and does not recommend CRP testing for high- or low-risk individuals: Class IIa (It is reasonable to perform the procedure) In men 50 years of age or older or women 60 years of age or older with LDL-C<130 mg/dl; not on lipid-lowering, HRT, or immunosuppressant therapy; without clinical CHD, diabetes, CKD, severe inflammatory conditions, or contraindications to statins, measurement of CRP can be useful in the selection of patients for statin therapy. Class IIb (Procedure may be considered) In asymptomatic intermediate-risk men aged <50 y or women >60 years of age Class III (No Benefit) In asymptomatic high-risk adults and in low-risk men <50 years of age or women <60 years of age

28 CRP for the Clinician Summary/Conclusions CRP is a marker of inflammation and a predictor of CV risk, however, it provides modest additional information over and above that afforded by conventional clinical markers Screening of the entire adult population is not recommended Measurement of hs-crp in high risk subjects is unlikely to influence patient evaluation or therapy In some patients at intermediate risk for CHD (10 to 20% at 10 years by FRS) hs-crp may help direct further evaluation and therapy for primary prevention. A high CRP might be treated as an additional risk factor when determining BP or LDL-cholesterol control targets

JUPITER NEJM Poll. Panel Discussion: Literature that Should Have an Impact on our Practice: The JUPITER Study

JUPITER NEJM Poll. Panel Discussion: Literature that Should Have an Impact on our Practice: The JUPITER Study Panel Discussion: Literature that Should Have an Impact on our Practice: The Study Kaiser COAST 11 th Annual Conference Maui, August 2009 Robert Blumberg, MD, FACC Ralph Brindis, MD, MPH, FACC Primary

More information

John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam

John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam Latest Insights from the JUPITER Study John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam Inflammation, hscrp, and Vascular Prevention

More information

LDL cholesterol and cardiovascular outcomes?

LDL cholesterol and cardiovascular outcomes? LDL cholesterol and cardiovascular outcomes? Prof Kausik Ray, BSc (hons), MBChB, FRCP, MD, MPhil (Cantab), FACC, FESC Professor of Cardiovascular Disease Prevention St Georges University of London Honorary

More information

Inflammation and and Heart Heart Disease in Women Inflammation and Heart Disease

Inflammation and and Heart Heart Disease in Women Inflammation and Heart Disease Inflammation and Heart Disease in Women Inflammation and Heart Disease What is the link between een inflammation and atherosclerotic disease? What is the role of biomarkers in predicting cardiovascular

More information

The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009

The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009 The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009 Learning Objectives 1. Understand the role of statin therapy in the primary and secondary prevention of stroke 2. Explain

More information

The Clinical Unmet need in the patient with Diabetes and ACS

The Clinical Unmet need in the patient with Diabetes and ACS The Clinical Unmet need in the patient with Diabetes and ACS Professor Kausik Ray (UK) BSc(hons), MBChB, MD, MPhil, FRCP (lon), FRCP (ed), FACC, FESC, FAHA Diabetes is a global public health challenge

More information

Dyslipidemia in women: Who should be treated and how?

Dyslipidemia in women: Who should be treated and how? Dyslipidemia in women: Who should be treated and how? Lale Tokgozoglu, MD, FACC, FESC Professor of Cardiology Hacettepe University Faculty of Medicine Ankara, Turkey. Cause of Death in Women: European

More information

CVD risk assessment using risk scores in primary and secondary prevention

CVD risk assessment using risk scores in primary and secondary prevention CVD risk assessment using risk scores in primary and secondary prevention Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil Disclosure Honoraria for consulting and speaker activities

More information

Review of guidelines for management of dyslipidemia in diabetic patients

Review of guidelines for management of dyslipidemia in diabetic patients 2012 international Conference on Diabetes and metabolism (ICDM) Review of guidelines for management of dyslipidemia in diabetic patients Nan Hee Kim, MD, PhD Department of Internal Medicine, Korea University

More information

Treatment of Cardiovascular Risk Factors. Kevin M Hayes D.O. F.A.C.C. First Coast Heart and Vascular Center

Treatment of Cardiovascular Risk Factors. Kevin M Hayes D.O. F.A.C.C. First Coast Heart and Vascular Center Treatment of Cardiovascular Risk Factors Kevin M Hayes D.O. F.A.C.C. First Coast Heart and Vascular Center Disclosures: None Objectives What do risk factors tell us What to check and when Does treatment

More information

Subclinical atherosclerosis in CVD: Risk stratification & management Raul Santos, MD

Subclinical atherosclerosis in CVD: Risk stratification & management Raul Santos, MD Subclinical atherosclerosis in CVD: Risk stratification & management Raul Santos, MD Sao Paulo Medical School Sao Paolo, Brazil Subclinical atherosclerosis in CVD risk: Stratification & management Prof.

More information

Inflammation as A Target for Therapy. Focus on Residual Inflammatory Risk

Inflammation as A Target for Therapy. Focus on Residual Inflammatory Risk ESC Rome Monday August 29, 2016 Inflammation as A Target for Therapy Focus on Residual Inflammatory Risk Paul M Ridker, MD Eugene Braunwald Professor of Medicine Harvard Medical School Director, Center

More information

Evaluation of C-reactive protein prior to and on-treatment as a predictor of benefit

Evaluation of C-reactive protein prior to and on-treatment as a predictor of benefit Evaluation of C-reactive protein prior to and on-treatment as a predictor of benefit from atorvastatin. A cohort analysis from the Anglo-Scandinavian Cardiac Outcomes Trial Lipid-Lowering Arm Peter S Sever,

More information

Weintraub, W et al NEJM March Khot, UN et al, JAMA 2003

Weintraub, W et al NEJM March Khot, UN et al, JAMA 2003 Global risk hscrp Should not be included in a Global Cardiovascular Risk Assessment. Jodi Tinkel, MD Assistant Professor Director of Cardiac Rehabilitation Associate Program Director, Cardiovascular Medicine

More information

Rikshospitalet, University of Oslo

Rikshospitalet, University of Oslo Rikshospitalet, University of Oslo Preventing heart failure by preventing coronary artery disease progression European Society of Cardiology Dyslipidemia 29.08.2010 Objectives The trends in cardiovascular

More information

1. Which one of the following patients does not need to be screened for hyperlipidemia:

1. Which one of the following patients does not need to be screened for hyperlipidemia: Questions: 1. Which one of the following patients does not need to be screened for hyperlipidemia: a) Diabetes mellitus b) Hypertension c) Family history of premature coronary disease (first degree relatives:

More information

Case Presentation. Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer

Case Presentation. Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer Case Presentation Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer Case Presentation 50 YO man NSTEMI treated with PCI 1 month ago Medical History: Obesity: BMI 32,

More information

Statins for Cardiovascular Disease Prevention in Women: Review of the Evidence

Statins for Cardiovascular Disease Prevention in Women: Review of the Evidence Statins for Cardiovascular Disease Prevention in Women: Review of the Evidence Karen E. Aspry, M.D., M.S., ABCL, FACC Assistant Professor of Medicine (Clinical) Alpert Medical School of Brown University

More information

What have We Learned in Dyslipidemia Management Since the Publication of the 2013 ACC/AHA Guideline?

What have We Learned in Dyslipidemia Management Since the Publication of the 2013 ACC/AHA Guideline? What have We Learned in Dyslipidemia Management Since the Publication of the 2013 ACC/AHA Guideline? Salim S. Virani, MD, PhD, FACC, FAHA Associate Professor, Section of Cardiovascular Research Baylor

More information

Decline in CV-Mortality

Decline in CV-Mortality Lipids id 2013 What s Changed? Christopher Granger, MD Disclosure Research contracts: AstraZeneca, GSK, Merck, Sanofi- Aventis, BMS, Pfizer, The Medicines Company, Medtronic Foundation, and Boehringer

More information

Correlation of novel cardiac marker

Correlation of novel cardiac marker Correlation of novel cardiac marker and mortality in EGAT population. Soluble ST2 hscrp Poh Chanyavanich, MD SukitYamwong, MD Piyamitr Sritara, MD Ramathibodi hospital Background hscrp - the most widely

More information

Financial Disclosures. Coronary Artery Calcification. Objectives. Coronary Artery Calcium 6/6/2018. Heart Disease Statistics At-a-Glace 2017

Financial Disclosures. Coronary Artery Calcification. Objectives. Coronary Artery Calcium 6/6/2018. Heart Disease Statistics At-a-Glace 2017 Coronary Artery Calcification Dharmendra A. Patel, MD MPH Director, Echocardiography Laboratory Associate Program Director Cardiovascular Disease Fellowship Program Erlanger Heart and Lung Institute UT

More information

Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS)

Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS) Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS) Stable CAD (post MI) On Statin, ACE/ARB, BB, ASA Persistent Elevation of hscrp (> 2 mg/l) N = 10,061 39 Countries April 2011 - June 2017

More information

Dyslipidemia: Lots of Good Evidence, Less Good Interpretation.

Dyslipidemia: Lots of Good Evidence, Less Good Interpretation. Dyslipidemia: Lots of Good Evidence, Less Good Interpretation. G Michael Allan Evidence & CPD Program, ACFP Associate Professor, Dept of Family, U of A. CFPC CoI Templates: Slide 1 Faculty/Presenter Disclosure

More information

ATP IV: Predicting Guideline Updates

ATP IV: Predicting Guideline Updates Disclosures ATP IV: Predicting Guideline Updates Daniel M. Riche, Pharm.D., BCPS, CDE Speaker s Bureau Merck Janssen Boehringer-Ingelheim Learning Objectives Describe at least two evidence-based recommendations

More information

Welcome! Mark May 14, Sat!

Welcome! Mark May 14, Sat! Welcome! Mark May 14, Sat! Do We Have All Answers with Statins In Treating Patients with Hyperlipidemia? Kwang Kon Koh, MD, PhD, FACC, FAHA Cardiology, Gil Heart Center, Gachon Medical School, Incheon,

More information

Is Lower Better for LDL or is there a Sweet Spot

Is Lower Better for LDL or is there a Sweet Spot Is Lower Better for LDL or is there a Sweet Spot ALAN S BROWN MD, FACC FNLA FAHA FASPC DIRECTOR, DIVISION OF CARDIOLOGY ADVOCATE LUTHERAN GENERAL HOSPITAL, PARK RIDGE, ILLINOIS DIRECTOR OF CARDIOLOGY,

More information

Placebo-Controlled Statin Trials EXPLAINING THE DECREASE IN DEATHS FROM CHD! PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN EXPLAINING THE DECREASE IN

Placebo-Controlled Statin Trials EXPLAINING THE DECREASE IN DEATHS FROM CHD! PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN EXPLAINING THE DECREASE IN PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest EXPLAINING THE DECREASE

More information

Placebo-Controlled Statin Trials MANAGEMENT OF HIGH BLOOD CHOLESTEROL MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES

Placebo-Controlled Statin Trials MANAGEMENT OF HIGH BLOOD CHOLESTEROL MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest

More information

Expert Meeting on Large Simple Trials (LST s)

Expert Meeting on Large Simple Trials (LST s) Expert Meeting on Large Simple Trials (LST s) Clinical Trials Transformation Initiative Justification for the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin JUPITER Johannes

More information

Macrovascular Residual Risk. What risk remains after LDL-C management and intensive therapy?

Macrovascular Residual Risk. What risk remains after LDL-C management and intensive therapy? Macrovascular Residual Risk What risk remains after LDL-C management and intensive therapy? Defining Residual Vascular Risk The risk of macrovascular events and microvascular complications which persists

More information

Fasting or non fasting?

Fasting or non fasting? Vascular harmony Robert Chilton Professor of Medicine University of Texas Health Science Center Director of Cardiac Catheterization labs Director of clinical proteomics Which is best to measure Lower continues

More information

Dyslipidemia in the light of Current Guidelines - Do we change our Practice?

Dyslipidemia in the light of Current Guidelines - Do we change our Practice? Dyslipidemia in the light of Current Guidelines - Do we change our Practice? Dato Dr. David Chew Soon Ping Senior Consultant Cardiologist Institut Jantung Negara Atherosclerotic Cardiovascular Disease

More information

Ten Year Risk for CVD Event by Systolic HTN and CVD Risk Factors (Where s Age?)

Ten Year Risk for CVD Event by Systolic HTN and CVD Risk Factors (Where s Age?) Prevention and Treatment of CVD in Older Patients with Diabetes and Pre Diabetes: Hypertension and Dyslipidemia ASP Workshop on Diabetes Mellitus and Cardiovascular Disease in Older Adults Pentagon City

More information

The Framingham Coronary Heart Disease Risk Score

The Framingham Coronary Heart Disease Risk Score Plasma Concentration of C-Reactive Protein and the Calculated Framingham Coronary Heart Disease Risk Score Michelle A. Albert, MD, MPH; Robert J. Glynn, PhD; Paul M Ridker, MD, MPH Background Although

More information

Do Women Benefit From Statins for Primary Prevention?: Controversy, Challenges and Consensus

Do Women Benefit From Statins for Primary Prevention?: Controversy, Challenges and Consensus Do Women Benefit From Statins for Primary Prevention?: Controversy, Challenges and Consensus C. Noel Bairey Merz MD, FACC, FAHA Professor and Women s Guild Endowed Chair Director, Barbra Streisand Women

More information

Preventing Cardiovascular Disease With Lipid Management: Matching Therapy to Risk

Preventing Cardiovascular Disease With Lipid Management: Matching Therapy to Risk PREVENTING CARDIOVASCULAR DISEASE WITH LIPID MANAGEMENT : MATCHING TREATMENT TO RISK Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict

More information

An example of a systematic review and meta-analysis

An example of a systematic review and meta-analysis An example of a systematic review and meta-analysis Sattar N et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010; 375: 735-742. Search strategy

More information

Should we treat everybody over 60 years with a statin? Comprehensive primary prevention in practice

Should we treat everybody over 60 years with a statin? Comprehensive primary prevention in practice Should we treat everybody over 60 years with a statin? Comprehensive primary prevention in practice Pathogenesis of atherosclerosis A decades-long disease course Inflammation Selectins ICAM IL M-CSF CRP

More information

No relevant financial relationships

No relevant financial relationships MANAGEMENT OF LIPID DISORDERS Balancing Benefits and harms Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial relationships baron@medicine.ucsf.edu

More information

Beyond Framingham: Risk Assessment & Treatment for Primary Prevention

Beyond Framingham: Risk Assessment & Treatment for Primary Prevention Beyond Framingham: Risk Assessment & Treatment for Primary Prevention Ronald M. Goldenberg, MD, FRCPC, FACE Consultant Endocrinologist, North York General Hospital Medical Co-Director, LMC Endocrinology

More information

JAMA. 2011;305(24): Nora A. Kalagi, MSc

JAMA. 2011;305(24): Nora A. Kalagi, MSc JAMA. 2011;305(24):2556-2564 By Nora A. Kalagi, MSc Cardiovascular disease (CVD) is the number one cause of mortality and morbidity world wide Reducing high blood cholesterol which is a risk factor for

More information

Learning Objectives. Predicting and Preventing Cardiovascular Disease. ACC/AHA Cholesterol Guidelines Key differences vs ATP III

Learning Objectives. Predicting and Preventing Cardiovascular Disease. ACC/AHA Cholesterol Guidelines Key differences vs ATP III Presenter Disclosure Information 10:30 11:15am Predicting and Preventing Cardiovascular Disease: Can we put the Cardiologist out of business? The following relationships exist related to this presentation:

More information

Traitements associés chez l hypertendu: Statines, Aspirine

Traitements associés chez l hypertendu: Statines, Aspirine Traitements associés chez l hypertendu: Statines, Aspirine Pr Jean-Jacques Mourad CHU Avicenne, Université Paris 13, Bobigny DU HTA, Mars 2012 jean-jacques.mourad@avc.aphp.fr Global Mortality 2000: Impact

More information

Disclosures. Objectives. Cardiovascular Risk. Patient Case. JUPITER: The final frontier in statin utilization or an idea from outer space?

Disclosures. Objectives. Cardiovascular Risk. Patient Case. JUPITER: The final frontier in statin utilization or an idea from outer space? Disclosures JUPITER: The final frontier in statin utilization or an idea from outer space? Kathy E. Komperda, PharmD, BCPS Midwestern University Chicago College of Pharmacy kkompe@midwestern.edu 4/25/09

More information

Should we prescribe aspirin and statins to all subjects over 65? (Or even all over 55?) Terje R.Pedersen Oslo University Hospital Oslo, Norway

Should we prescribe aspirin and statins to all subjects over 65? (Or even all over 55?) Terje R.Pedersen Oslo University Hospital Oslo, Norway Should we prescribe aspirin and statins to all subjects over 65? (Or even all over 55?) Terje R.Pedersen Oslo University Hospital Oslo, Norway The Polypill A strategy to reduce cardiovascular disease by

More information

PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN

PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest EXPLAINING THE DECREASE

More information

Best Lipid Treatments

Best Lipid Treatments Best Lipid Treatments Pam R. Taub MD, FACC Director of Step Family Cardiac Rehabilitation and Wellness Center Associate Professor of Medicine UC San Diego Health System Overview of Talk Review of pathogenesis

More information

Biomarkers in Cardiovascular Diseases. Peter Ganz, MD. Chief, Division of Cardiology, San Francisco General Hospital

Biomarkers in Cardiovascular Diseases. Peter Ganz, MD. Chief, Division of Cardiology, San Francisco General Hospital Biomarkers in Cardiovascular Diseases Peter Ganz, MD Chief, Division of Cardiology, San Francisco General Hospital Maurice Eliaser Jr. Distinguished Professor of Medicine, University of California, San

More information

Does High-Intensity Pitavastatin Therapy Further Improve Clinical Outcomes?

Does High-Intensity Pitavastatin Therapy Further Improve Clinical Outcomes? Late Breaking Clinical Trial Session at AHA 2017 Does High-Intensity Pitavastatin Therapy Further Improve Clinical Outcomes? The REAL-CAD Study in 13,054 Patients With Stable Coronary Artery Disease Takeshi

More information

The Clinical Debates

The Clinical Debates The Clinical Debates Speakers: Round 2: Statins for Primary Prevention of Cardiovascular Disease Matthew Cantrell, PharmD, BCPS, is a 2000 graduate of Mt. Mercy College and 2005 graduate from the University

More information

Assessing Cardiovascular Risk to Optimally Stratify Low- and Moderate- Risk Patients. Copyright. Not for Sale or Commercial Distribution

Assessing Cardiovascular Risk to Optimally Stratify Low- and Moderate- Risk Patients. Copyright. Not for Sale or Commercial Distribution CLINICAL Viewpoint Assessing Cardiovascular Risk to Optimally Stratify Low- and Moderate- Risk Patients Copyright Not for Sale or Commercial Distribution By Ruth McPherson, MD, PhD, FRCPC Unauthorised

More information

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 6 October 2010

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 6 October 2010 The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 6 October 2010 CRESTOR 5 mg, film-coated tablet B/30 (CIP code: 369 853-8) B/90 (CIP code: 391 690-0) CRESTOR 10 mg,

More information

How to Reduce Residual Risk in Primary Prevention

How to Reduce Residual Risk in Primary Prevention How to Reduce Residual Risk in Primary Prevention Helene Glassberg, MD Assistant Professor of Medicine Section of Cardiology Hospital of the University of Pennsylvania Philadelphia, PA USA Patients with

More information

New Lipid Guidelines. PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids.

New Lipid Guidelines. PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids. PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Disclosure No relevant

More information

Role of imaging in risk assessment models: the example of CIMT

Role of imaging in risk assessment models: the example of CIMT Role of imaging in risk assessment models: the example of CIMT Diederick E. Grobbee, MD, PhD, FESC Professor of Clinical Epidemiology Julius Center for Health Sciences and Primary Care, University Medical

More information

ESC Geoffrey Rose Lecture on Population Sciences Cholesterol and risk: past, present and future

ESC Geoffrey Rose Lecture on Population Sciences Cholesterol and risk: past, present and future ESC Geoffrey Rose Lecture on Population Sciences Cholesterol and risk: past, present and future Rory Collins BHF Professor of Medicine & Epidemiology Clinical Trial Service Unit & Epidemiological Studies

More information

Contemporary management of Dyslipidemia

Contemporary management of Dyslipidemia Contemporary management of Dyslipidemia Todd Anderson Feb 2018 Disclosure Statement Within the past two years: I have not had an affiliation (financial or otherwise) with a commercial organization that

More information

9/18/2017 DISCLOSURES. Consultant: RubiconMD. Research: Amgen, NHLBI OUTLINE OBJECTIVES. Review current CV risk assessment tools.

9/18/2017 DISCLOSURES. Consultant: RubiconMD. Research: Amgen, NHLBI OUTLINE OBJECTIVES. Review current CV risk assessment tools. UW MEDICINE UW MEDICINE UCSF ASIAN TITLE HEALTH OR EVENT SYMPOSIUM 2017 DISCLOSURES Consultant: RubiconMD ESTIMATING CV RISK IN ASIAN AMERICANS AND PREVENTION OF CVD Research: Amgen, NHLBI EUGENE YANG,

More information

Should I use statins?

Should I use statins? I know the trials in heart failure but how do I manage my patient? Should I use statins? Aldo P Maggioni, MD, FESC ANMCO Research Center Firenze, Italy Disclosures Aldo P Maggioni served as a member of

More information

Considerations and Controversies in the Management of Dyslipidemia for ASCVD Risk Reduction

Considerations and Controversies in the Management of Dyslipidemia for ASCVD Risk Reduction Considerations and Controversies in the Management of Dyslipidemia for ASCVD Risk Reduction Pamela B. Morris, MD, FACC, FAHA, FASCP, FNLA Chair, ACC Prevention of Cardiovascular Disease Council The Medical

More information

Placebo-Controlled Statin Trials Prevention Of CVD in Women"

Placebo-Controlled Statin Trials Prevention Of CVD in Women MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest

More information

New evidences in heart failure: the GISSI-HF trial. Aldo P Maggioni, MD ANMCO Research Center Firenze, Italy

New evidences in heart failure: the GISSI-HF trial. Aldo P Maggioni, MD ANMCO Research Center Firenze, Italy New evidences in heart failure: the GISSI-HF trial Aldo P Maggioni, MD ANMCO Research Center Firenze, Italy % Improving survival in chronic HF and LV systolic dysfunction: 1 year all-cause mortality 20

More information

Therapeutic Implications of Vascular Inflammation: The Cardiovascular Inflammation Reduction Trials

Therapeutic Implications of Vascular Inflammation: The Cardiovascular Inflammation Reduction Trials Therapeutic Implications of Vascular Inflammation: The Cardiovascular Inflammation Reduction Trials ESC Munich August 25, 2012 Paul M Ridker, MD Eugene Braunwald Professor of Medicine Harvard Medical School

More information

Introduction. Objective. Critical Questions Addressed

Introduction. Objective. Critical Questions Addressed Introduction Objective To provide a strong evidence-based foundation for the treatment of cholesterol for the primary and secondary prevention of ASCVD in women and men Critical Questions Addressed CQ1:

More information

Inflammation, the Inflammasome and CAD Do Cardiologists need to know this? Jacques Genest MD

Inflammation, the Inflammasome and CAD Do Cardiologists need to know this? Jacques Genest MD Inflammation, the Inflammasome and CAD Do Cardiologists need to know this? Jacques Genest MD Cardiovascular Research Laboratories Research Institute of the McGill University Health Center Disclosure J.

More information

Prospective Natural-History Study of Coronary Atherosclerosis

Prospective Natural-History Study of Coronary Atherosclerosis Introduction Review of literature from April 2010 to present Concentrated on clinical studies Categories: Atherosclerosis, Lipids, Diabetes and CVD Risk Medical Therapy Statins really could there be anything

More information

Is there a mechanism of interaction between hypertension and dyslipidaemia?

Is there a mechanism of interaction between hypertension and dyslipidaemia? Is there a mechanism of interaction between hypertension and dyslipidaemia? Neil R Poulter International Centre for Circulatory Health NHLI, Imperial College London Daegu, Korea April 2005 Observational

More information

Low-density lipoprotein as the key factor in atherogenesis too high, too long, or both

Low-density lipoprotein as the key factor in atherogenesis too high, too long, or both Low-density lipoprotein as the key factor in atherogenesis too high, too long, or both Lluís Masana Vascular Medicine and Metabolism Unit. Sant Joan University Hospital. IISPV. CIBERDEM Rovira i Virgili

More information

Är dagens troponinmetoder tillräckligt känsliga?

Är dagens troponinmetoder tillräckligt känsliga? Är dagens troponinmetoder tillräckligt känsliga? Per Venge, MD PhD Professor Department of Medical Sciences Uppsala University and Department of Clinical Chemistry and Pharmacology University Hospital

More information

Copyright 2017 by Sea Courses Inc.

Copyright 2017 by Sea Courses Inc. Diabetes and Lipids Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any means graphic, electronic, or

More information

PCSK9 Inhibitors and Modulators

PCSK9 Inhibitors and Modulators PCSK9 Inhibitors and Modulators Pam R. Taub MD, FACC Director of Step Family Cardiac Rehabilitation and Wellness Center Associate Professor of Medicine UC San Diego Health System Disclosures Speaker s

More information

Lipid Management C. Samuel Ledford, MD Interventional Cardiology Chattanooga Heart Institute

Lipid Management C. Samuel Ledford, MD Interventional Cardiology Chattanooga Heart Institute Lipid Management 2018 C. Samuel Ledford, MD Interventional Cardiology Chattanooga Heart Institute Disclosures No Financial Disclosures Disclosures I am an Interventional Cardiologist I put STENTS in for

More information

Hyperlipidemia: Lowering the Bar on the Lipid Limbo. Community Faculty Development Symposium March 13, 2004 Hugh Huizenga MD, MPH

Hyperlipidemia: Lowering the Bar on the Lipid Limbo. Community Faculty Development Symposium March 13, 2004 Hugh Huizenga MD, MPH Mark slides Hyperlipidemia: Lowering the Bar on the Lipid Limbo Community Faculty Development Symposium March 13, 2004 Hugh Huizenga MD, MPH Hyperlipidemia is a common problem Nearly 50% of men in the

More information

9/29/2015. Primary Prevention of Heart Disease: Objectives. Objectives. What works? What doesn t?

9/29/2015. Primary Prevention of Heart Disease: Objectives. Objectives. What works? What doesn t? Primary Prevention of Heart Disease: What works? What doesn t? Samia Mora, MD, MHS Associate Professor, Harvard Medical School Associate Physician, Brigham and Women s Hospital October 2, 2015 Financial

More information

Marshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona,

Marshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona, Marshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona, Jamaica At the end of this presentation the participant

More information

Sanjay Kaul, MD, FACC, FAHA Division of Cardiology Cedars-Sinai Medical Center Los Angeles, California

Sanjay Kaul, MD, FACC, FAHA Division of Cardiology Cedars-Sinai Medical Center Los Angeles, California Targeting Inflammation in Atherosclerosis: Has CANTOS Nailed It? Controversies and Advances in the Treatment of Cardiovascular Disease The Seventeenth in the Series Beverly Hills, November 16, 2017 Sanjay

More information

New ACC/AHA Guidelines on Lipids: Are PCSK9 Inhibitors Poised for a Breakthrough?

New ACC/AHA Guidelines on Lipids: Are PCSK9 Inhibitors Poised for a Breakthrough? New ACC/AHA Guidelines on Lipids: Are PCSK9 Inhibitors Poised for a Breakthrough? Sidney C. Smith, Jr. MD, FACC, FAHA Professor of Medicine/Cardiology University of North Carolina at Chapel Hill Immediate

More information

High Sensitivity Troponin Improves Management. But Not Yet

High Sensitivity Troponin Improves Management. But Not Yet High Sensitivity Troponin Improves Management But Not Yet Allan S. Jaffe, MD.* Consultant - Cardiology & Laboratory Medicine Professor of Medicine Chair, CCLS Division, Department of Laboratory Medicine

More information

Current and Future Imaging Trends in Risk Stratification for CAD

Current and Future Imaging Trends in Risk Stratification for CAD Current and Future Imaging Trends in Risk Stratification for CAD Brian P. Griffin, MD FACC Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic Disclosures: None Introduction

More information

Managing Dyslipidemia in Disclosures. Learning Objectives 03/05/2018. Speaker Disclosures

Managing Dyslipidemia in Disclosures. Learning Objectives 03/05/2018. Speaker Disclosures Managing Dyslipidemia in 2018 Glen J. Pearson, BSc, BScPhm, PharmD, FCSHP, FCCS Professor of Medicine (Cardiology) Co-Director, Cardiac Transplant Clinic; Associate Chair, Health Research Ethics Boards;

More information

Summary HTA. HTA-Report Summary

Summary HTA. HTA-Report Summary Summary HTA HTA-Report Summary Prognostic value, clinical effectiveness and cost-effectiveness of high sensitivity C-reactive protein as a marker in primary prevention of major cardiac events Schnell-Inderst

More information

Reducing Inflammation to Reduce Cardiovascular Risk: The Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS)

Reducing Inflammation to Reduce Cardiovascular Risk: The Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS) New York City Cardiovascular Symposium December 10, 2017 Reducing Inflammation to Reduce Cardiovascular Risk: The Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS) Paul M Ridker, MD, MPH

More information

The Art of Cardiovascular Risk Assessment

The Art of Cardiovascular Risk Assessment The Art of Cardiovascular Risk Assessment Laurence S. Sperling, M.D., FACC, FACP,FAHA, FASPC Professor of Medicine (Cardiology) Professor of Global Health Director- Center for Heart Disease Prevention

More information

Lifetime clinical and economic benefits of statin-based LDL lowering in the 20-year Followup of the West of Scotland Coronary Prevention Study

Lifetime clinical and economic benefits of statin-based LDL lowering in the 20-year Followup of the West of Scotland Coronary Prevention Study Lifetime clinical and economic benefits of statin-based LDL lowering in the 20-year Followup of the West of Scotland Coronary Prevention Study Harvey White Green Lane Cardiovascular Service and Cardiovascular

More information

Trial to Reduce. Aranesp* Therapy. Cardiovascular Events with

Trial to Reduce. Aranesp* Therapy. Cardiovascular Events with Trial to Reduce Cardiovascular Events with Aranesp* Therapy John J.V. McMurray, Hajime Uno, Petr Jarolim, Akshay S. Desai, Dick de Zeeuw, Kai-Uwe Eckardt, Peter Ivanovich, Andrew S. Levey, Eldrin F. Lewis,

More information

David Y. Gaitonde, MD, FACP Endocrinology DDEAMC, Fort Gordon

David Y. Gaitonde, MD, FACP Endocrinology DDEAMC, Fort Gordon David Y. Gaitonde, MD, FACP Endocrinology DDEAMC, Fort Gordon I have no actual or potential conflicts of interest in relation to this program or presentation. Raphael School of Athens, 1509-1511 Apply

More information

Effective Treatment Options With Add-on or Combination Therapy. Christie Ballantyne (USA)

Effective Treatment Options With Add-on or Combination Therapy. Christie Ballantyne (USA) Effective Treatment Options With Add-on or Combination Therapy Christie Ballantyne (USA) Effective treatment options with add-on or combination therapy Christie M. Ballantyne, MD Center for Cardiovascular

More information

Eugene Barrett M.D., Ph.D. University of Virginia 6/18/2007. Diagnosis and what is it Glucose Tolerance Categories FPG

Eugene Barrett M.D., Ph.D. University of Virginia 6/18/2007. Diagnosis and what is it Glucose Tolerance Categories FPG Diabetes Mellitus: Update 7 What is the unifying basis of this vascular disease? Eugene J. Barrett, MD, PhD Professor of Internal Medicine and Pediatrics Director, Diabetes Center and GCRC Health System

More information

Changing lipid-lowering guidelines: whom to treat and how low to go

Changing lipid-lowering guidelines: whom to treat and how low to go European Heart Journal Supplements (2005) 7 (Supplement A), A12 A19 doi:10.1093/eurheartj/sui003 Changing lipid-lowering guidelines: whom to treat and how low to go C.M. Ballantyne Section of Atherosclerosis,

More information

New Paradigms in Predicting CVD Risk

New Paradigms in Predicting CVD Risk New Paradigms in Predicting CVD Risk Imaging as an Integrator of Lifetime Risk Exposure Michael J. Blaha MD MPH Presented by: Michael J. Blaha September 24, 2014 1 Talk Outline Risk factors vs. Disease

More information

Lessons from Recent Atherosclerosis Trials

Lessons from Recent Atherosclerosis Trials Lessons from Recent Atherosclerosis Trials Han, Ki Hoon MD PhD Asan Medical Center Seoul, Korea Change of concept Primary vs. secondary prevention Low risk vs. High risk High Risk CHD and equivalents CHD

More information

Landmark Clinical Trials.

Landmark Clinical Trials. Landmark Clinical Trials 1 Learning Objectives Discuss clinical trials and their role in lipid and lipoprotein treatment in cardiovascular prevention. Review the clinical trials of lipid-altering drug

More information

APPENDIX B: LIST OF THE SELECTED SECONDARY STUDIES

APPENDIX B: LIST OF THE SELECTED SECONDARY STUDIES APPENDIX B: LIST OF THE SELECTED SECONDARY STUDIES Main systematic reviews secondary studies on the general effectiveness of statins in secondary cardiovascular prevention (search date: 2003-2006) NICE.

More information

Controversies in Preventative Cardiology

Controversies in Preventative Cardiology Controversies in Preventative Cardiology Francisco Lopez-Jimenez, M.D., M.Sc, FACC, FAHA Professor of Medicine, Mayo Medical School Chair, Division of Preventive Cardiology Co-Director, Artificial Intelligence

More information

Current Cholesterol Guidelines and Treatment of Residual Risk COPYRIGHT. J. Peter Oettgen, MD

Current Cholesterol Guidelines and Treatment of Residual Risk COPYRIGHT. J. Peter Oettgen, MD Current Cholesterol Guidelines and Treatment of Residual Risk J. Peter Oettgen, MD Associate Professor of Medicine Harvard Medical School Director, Preventive Cardiology Beth Israel Deaconess Medical Center

More information

CVD Prevention, Who to Consider

CVD Prevention, Who to Consider Continuing Professional Development 3rd annual McGill CME Cruise September 20 27, 2015 CVD Prevention, Who to Consider Dr. Guy Tremblay Excellence in Health Care and Lifelong Learning Global CV risk assessment..

More information

Val-MARC: Valsartan-Managing Blood Pressure Aggressively and Evaluating Reductions in hs-crp

Val-MARC: Valsartan-Managing Blood Pressure Aggressively and Evaluating Reductions in hs-crp Página 1 de 5 Return to Medscape coverage of: American Society of Hypertension 21st Annual Scientific Meeting and Exposition Val-MARC: Valsartan-Managing Blood Pressure Aggressively and Evaluating Reductions

More information

Natriuretic peptides and cardiovascular diseases: from old concepts to novel perspectives

Natriuretic peptides and cardiovascular diseases: from old concepts to novel perspectives Natriuretic peptides and cardiovascular diseases: from old concepts to novel perspectives Speranza Rubattu, M.D. School of Medicine and Psychology, Sapienza University, Rome, Italy Natriuretic peptides

More information

The TNT Trial Is It Time to Shift Our Goals in Clinical

The TNT Trial Is It Time to Shift Our Goals in Clinical The TNT Trial Is It Time to Shift Our Goals in Clinical Angioplasty Summit Luncheon Symposium Korea Assoc Prof David Colquhoun 29 April 2005 University of Queensland, Wesley Hospital, Brisbane, Australia

More information